Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) - Total Assets
Based on the latest financial reports, Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) holds total assets worth NT$4.44 Billion TWD (≈ $139.84 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Chunghwa Chemical Synthesis & Biotech Co (1762) shareholders funds for net asset value and shareholders' equity analysis.
Chunghwa Chemical Synthesis & Biotech Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data.
Chunghwa Chemical Synthesis & Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Chunghwa Chemical Synthesis & Biotech Co Ltd's total assets of NT$4.44 Billion consist of 30.3% current assets and 69.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 4.7% |
| Accounts Receivable | NT$199.30 Million | 4.2% |
| Inventory | NT$969.00 Million | 20.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.77 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Chunghwa Chemical Synthesis & Biotech Co.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chunghwa Chemical Synthesis & Biotech Co Ltd's current assets represent 30.3% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2024, up from 2.1% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 20.4% of total assets.
Chunghwa Chemical Synthesis & Biotech Co Ltd Competitors by Total Assets
Key competitors of Chunghwa Chemical Synthesis & Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Chunghwa Chemical Synthesis & Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.34 | 2.81 | 2.50 |
| Quick Ratio | 1.10 | 0.92 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$820.46 Million | NT$995.97 Million | NT$601.44 Million |
Chunghwa Chemical Synthesis & Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Chunghwa Chemical Synthesis & Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.64 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | NT$4.76 Billion |
| Market Capitalization | $68.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chunghwa Chemical Synthesis & Biotech Co Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Chunghwa Chemical Synthesis & Biotech Co Ltd's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2024)
The table below shows the annual total assets of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$4.76 Billion ≈ $150.05 Million |
-7.91% |
| 2023-12-31 | NT$5.17 Billion ≈ $162.94 Million |
+13.31% |
| 2022-12-31 | NT$4.56 Billion ≈ $143.80 Million |
+4.19% |
| 2021-12-31 | NT$4.38 Billion ≈ $138.02 Million |
+39.20% |
| 2020-12-31 | NT$3.15 Billion ≈ $99.15 Million |
-8.48% |
| 2019-12-31 | NT$3.44 Billion ≈ $108.34 Million |
+6.75% |
| 2018-12-31 | NT$3.22 Billion ≈ $101.49 Million |
-6.57% |
| 2017-12-31 | NT$3.45 Billion ≈ $108.63 Million |
+26.50% |
| 2016-12-31 | NT$2.73 Billion ≈ $85.87 Million |
-5.05% |
| 2015-12-31 | NT$2.87 Billion ≈ $90.44 Million |
-10.50% |
| 2014-12-31 | NT$3.21 Billion ≈ $101.05 Million |
+5.50% |
| 2013-12-31 | NT$3.04 Billion ≈ $95.78 Million |
+0.82% |
| 2012-12-31 | NT$3.02 Billion ≈ $95.00 Million |
+26.96% |
| 2011-12-31 | NT$2.38 Billion ≈ $74.83 Million |
+0.19% |
| 2010-12-31 | NT$2.37 Billion ≈ $74.68 Million |
+2.52% |
| 2009-12-31 | NT$2.31 Billion ≈ $72.85 Million |
+1.57% |
| 2008-12-31 | NT$2.28 Billion ≈ $71.72 Million |
-- |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more